Skip to main content
. 2016 Nov 12;8(1):191–202. doi: 10.18632/oncotarget.13329

Figure 5. IGFBP2 expression is a validated prognostic marker within IDH-mutant glioma.

Figure 5

A. and B. Correlations of IGFBP2 mRNA levels with overall survival A. and disease-free survival B. of IDH-wildtype patients (in black) and IDH-mutant patients (in blue) were analyzed in log-rank (Mantel-Cox) tests. C.-E. The GSE16011 glioma data set was used for validation of IGFBP2 as a prognostic marker in gene expression between IDH1R132H-negative and IDH1R132H-positive gliomas C., and overall survival of all glioma patients D. and patients stratified based on IDH status E. with respect to IGFBP2 expression. IDH1R132H-negative is in black, and IDH1R132H-positive in blue.